磷酸烯醇式丙酮酸羧激酶1对胃癌细胞生物学行为的影响及相关机制

摘要
图/表
参考文献(0)
相关文章 (11)

全文: PDF (26316 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

文章导读

摘要目的：探讨磷酸烯醇式丙酮酸羧激酶1(phosphoenolpyruvate carboxykinase 1，PCK1)在胃癌中的表达、与胃癌患者预后的关系及其潜在机制。方法：利用TCGA数据库、HPA数据库及Oncomine 4.5数据库中胃癌以及癌旁组织的相关数据与图片，分析PCK1表达水平与胃癌患者临床病理学特征和总生存期的关系，采用基因功能富集分析(GSEA)预测PCK1调控胃癌潜在的信号通路。体外细胞学实验采用慢病毒转染胃癌HGC-27和AGS细胞，分别敲低与过表达PCK1，采用细胞功能学实验检测PCK1对胃癌细胞生长、增殖、迁移等影响，同时采用蛋白质免疫印迹检测相关蛋白的表达。结果：与癌旁组织相比，PCK1在胃癌组织中表达明显上调(P＜0.05)；ROC曲线提示PCK1对胃癌患者预后具有良好的预测效能；通过GSEA富集分析提示原发性免疫缺陷、细胞黏附分子、趋化因子信号通路、全身性红斑狼疮、产生IgA的肠道免疫网络及RIGⅠ样受体信号通路相关的基因集在PCK1基因低表达表型中差异富集；敲低PCK1后，胃癌HGC-27和AGS细胞生长、克隆形成能力、迁移能力显著下降，同时p-AKT(Ser473)、p-mTOR、p-S6和p-4EBP1表达水平明显降低(P＜0.05或P＜0.01)；过表达PCK1则与之作用相反。结论： PCK1在胃癌中呈高表达且与患者预后相关，其可能通过活化AKTmTOR信号通路促进胃癌细胞生长、增殖与迁移。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	沈昕草
	朱孝仁
	刘媛媛
	等.

关键词 ：胃癌font-family: ????, font-weight: 700, text-align: -webkit-right, ')" href="#">background-color: rgb(212, 226, 255);">, 磷酸烯醇式丙酮酸羧激酶1font-family: ????, font-weight: 700, text-align: -webkit-right, ')" href="#">background-color: rgb(212, 226, 255);">, 迁移font-family: ????, font-weight: 700, text-align: -webkit-right, ')" href="#">background-color: rgb(212, 226, 255);">, 增殖font-family: ????, font-weight: 700, text-align: -webkit-right, ')" href="#">background-color: rgb(212, 226, 255);">, AKT-mTOR信号通路

Abstract： Objective： To investigate the expression level of phosphoenolpyruvate carboxykinase 1(PCK1) in gastric cancer, its relationship with the prognosis of gastric cancer patients and its potential mechanism. Methods： By using the relevant data and images of gastric cancer and adjacent tissues in the TCGA database, HPA database and Oncomine 4.5 database, the relationship between the expression level of PCK1 and the clinicopathological features and overall survival of patients with gastric cancer was analyzed, and the potential signaling pathway of PCK1 regulation of gastric cancer was predicted by gene function enrichment analysis (GSEA). In vitro cytology experiment, lentivirus was used to transfect gastric cancer HGC-27 and AGS cells to knock down or over express PCK1, respectively. The effects of PCK1 on the growth, proliferation and migration of gastric cancer cells were detected by cell functional assay. And Western blotting was used to detect the expression of related proteins. Results： Compared with the adjacent tissues, PCK1 expression was significantly upregulated in gastric cancer tissues (P＜0.05); ROC curve suggested that PCK1 had a significant efficacy in predicting prognosis of gastric cancer patients; enrichment analysis by GSEA suggested that gene sets related to primary immunodeficiency, cell adhesion molecules, chemokine signalling pathway, systemic lupus erythematosus, IgAproducing intestinal immune network and RIGⅠtype receptor signalling pathway were differentially enriched in PCK1 gene low expression phenotype. Knockdown of PCK1, the growth, clonogenic capacity, and migration ability of gastric cancer HGC-27 and AGS cells were greatly decreased, and the expression levels of pAKT (Ser473), p-mTOR, p-S6 and p-4EBP1 were also markedly decreased (P<0.05 or P＜0.01); overexpression of PCK1 produced the opposite effect. Conclusion： PCK1 is highly expressed in gastric cancer and is associated with the prognosis of patients, which may promote the growth, proliferation and migration of gastric cancer cells by activating the AKT-mTOR signalling pathway.

Key words：

收稿日期: 2022-01-03

基金资助:

通讯作者: 吴晓阳(通讯作者)，硕士生导师，副教授，E-mail: 535550211@qq.com

作者简介: 沈昕草(1996—)，男，硕士研究生；

引用本文:

沈昕草，朱孝仁，刘媛媛，等.. 磷酸烯醇式丙酮酸羧激酶1对胃癌细胞生物学行为的影响及相关机制[J]. 江苏大学学报:医学版, 2023, 33(01): 9-16. SHEN Xincao1, ZHU Xiaoren1, LIU Yuanyuan2, WU Xiaoyang3. Effect of phosphoenolpyruvate carboxykinase 1 on the biological behavior

of gastric cancer cells and related mechanisms

. Journal of Jiangsu University(Medicine Edition), 2023, 33(01): 9-16.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2023/V33/I01/9

［1］Catenacci D, Tebbutt NC, Davidenko I, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as firstline therapy in advanced METpositive gastric or gastrooesophageal junction cancer (RILOMET1): a randomised, doubleblind, placebocontrolled, phase 3 trial［J］. Lancet Oncol, 2017, 18(11): 1467-1482.

［2］Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2): 115-132.

［3］Ilson DH, Tabernero J, Prokharau A, et al. Efficacy and safety of trifluridine/tipiracil treatment in patients with metastatic gastric cancer who had undergone gastrectomy: subgroup analyses of a randomized clinical trial［J］. JAMA Oncol, 2020, 6(1): e193531.

［4］Nagini S. Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention［J］. World J Gastrointest Oncol, 2012, 4(7): 156-169.

［5］Lamont BJ, Andrikopoulos S, Funkat A, et al. Peripheral insulin resistance develops in transgenic rats overexpressing phosphoenolpyruvate carboxykinase in the kidney［J］. Diabetologia, 2003, 46(10): 1338-1347.

［6］Watford M, Hod Y, Chiao YB, et al. The unique role of the kidney in gluconeogenesis in the chicken. The significance of a cytosolic form of phosphoenolpyruvate carboxykinase［J］. J Biol Chem, 1981, 256(19): 10023-10027.

［7］Yu S, Meng S, Xiang M, et al. Phosphoenolpyruvate carboxykinase in cell metabolism: Roles and mechanisms beyond gluconeogenesis［J］. Mol Metab, 2021, 53: 101257.

［8］Matsuoka H, Shima A, Kuramoto D, et al. Phosphoenolpyruvate carboxykinase, a key enzyme that controls blood glucose, is a target of retinoic acid receptorrelated orphan receptor α［J］. PLoS One, 2015, 10(9): e137955.

［9］Franckhauser S, Munoz S, Pujol A, et al. Increased fatty acid reesterification by PEPCK overexpression in adipose tissue leads to obesity without insulin resistance［J］. Diabetes, 2002, 51(3): 624-630.

［10］Montal ED, Dewi R, Bhalla K, et al. PEPCK coordinates the regulation of central carbon metabolism to promote cancer cell growth［J］. Mol Cell, 2015, 60(4): 571-583.

［11］Ma R, Ji T, Zhang H, et al. A Pck1directed glycogen metabolic program regulates formation and maintenance of memory CD8+ T cells［J］. Nat Cell Biol, 2018, 20(1): 21-27.

［12］Guo H, Chi Y, Chi N. Bioinformatis analysis reveals possible molecular mechanism of PXR on regulating ulcerative colitis［J］. Sci Rep, 2021, 11(1): 5428.

［13］Butler EB, Zhao Y, MunozPinedo C, et al. Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance［J］. Cancer Res, 2013, 73(9): 2709-2717.

［14］Xu D, Wang Z, Xia Y, et al. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis［J］. Nature, 2020, 580(7804): 530-535.

［15］Liu MX, Jin L, Sun SJ, et al. Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma［J］. Oncogene, 2018, 37(12): 1637-1653.

［16］Shi L, An S, Liu Y, et al. PCK1 regulates glycolysis and tumor progression in clear cell renal cell carcinoma through LDHA［J］. Onco Targets Ther, 2020, 13: 2613-2627.

［17］Shao F, Bian X, Wang J, et al. Prognostic impact of PCK1 protein kinase activitydependent nuclear SREBP1 activation in nonsmallcell lung carcinoma［J］. Front Oncol, 2021, 11: 561247.

［18］Stark R, GuebreEgziabher F, Zhao X, et al. A role for mitochondrial phosphoenolpyruvate carboxykinase (PEPCKM) in the regulation of hepatic gluconeogenesis［J］. J Biol Chem, 2014, 289(11): 7257-7263.

［19］Cluntun AA, Lukey MJ, Cerione RA, et al. Glutamine metabolism in cancer: understanding the heterogeneity［J］. Trends Cancer, 2017, 3(3): 169-180.

［20］Yamaguchi N, Weinberg EM, Nguyen A, et al. PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis［J］. Elife, 2019, 8: e52135.

［21］Fattahi S, AmjadiMoheb F, Tabaripour R, et al. PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond［J］. Life Sci, 2020, 262: 118513.

［22］Murugan AK. mTOR: Role in cancer, metastasis and drug resistance［J］. Semin Cancer Biol, 2019, 59: 92-111.

［23］GuerreroZotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment［J］. Cancer Metastasis Rev, 2016, 35(4): 515-524.

［24］Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance［J］. Semin Cancer Biol, 2019, 59: 147-160.

［25］Durn RV, Oppliger W, Robitaille AM, et al. Glutaminolysis activates RagmTORC1 signaling［J］. Mol Cell, 2012, 47(3): 349-358.

［26］Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer［J］. Nat Rev Cancer, 2018, 18(12): 744-757.

［27］Forest C, Beale E. New developments in nutrition and diabetes: glyceroneogenesis comes of age［J］. Biochimie, 2003, 85(12): 1195-1197.